BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NEO100 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NEO100\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05023018-10951@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:NEO100: Phase 2 readout est. (NCT05023018)
DESCRIPTION:NEO100\, phase 2.\nStudy: NEO100 and High-Grade Meningioma\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/neo100#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05023018
URL:https://assetmemo.bio/drug/neo100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357377-10951@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:NEO100: Phase 1 readout est. (NCT06357377)
DESCRIPTION:NEO100\, phase 1.\nStudy: A Study of the Safety\, Dosing\, and 
 Delivery of NEO100 in Patients With Pediatric Brain Tumors\nEstimated prim
 ary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/neo100#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06357377
URL:https://assetmemo.bio/drug/neo100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
